Skin infection

ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Wednesday, March 13, 2024
AXL, PIN, Neutropenia, Growth, Rituximab, Sarcoma, ALT, NSCLC, ASH, FY, Progression-free survival, Skin infection, Patient, Follicular lymphoma, S&M, Research, EDT, Aes, Periodic breathing, G&A, University, Lung cancer, Insurance, AACR, DLT, Pancreatic cancer, Hyperglycemia, Society, Therapy, Clinical trial, Diffuse large B-cell lymphoma, PFS, CD22, ADC, Data, Fatigue, MD Anderson Cancer Center, FDA, DLBCL, Marketing, PSMA, IDMC, Pharmaceutical industry

LAUSANNE, Switzerland, March 13, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided business updates.

Key Points: 
  • “In the fourth quarter we saw results of our strategy in action across a number of key areas.
  • A return to sequential quarter-over-quarter growth in the fourth quarter of 2023 followed the restructuring of the commercial model, with sales volume increasing in both community and academic settings.
  • R&D expenses were $30.3 million for the fourth quarter and $127.1 million for full year 2023, compared to $48.1 million and $186.5 million, respectively, for the fourth quarter and full year 2022.
  • ADC Therapeutics management will host a conference call and live audio webcast to discuss fourth quarter and full year 2023 financial results and provide a company update today at 8:30 a.m. Eastern Time.

Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)

Retrieved on: 
Tuesday, April 2, 2024
Health, Defense, Infectious Diseases, Pharmaceutical, Contracts, Biotechnology, Ulcer, Paromomycin, Patient, NTD, IND, Metronidazole, Francisella tularensis, Infection, OTCQX, Therapy, Priority review, USD, Risk, Systemic, NIH, Anthrax, Arrangement, World Health Organization, Investigational New Drug, Calendar, Scar, Neglected tropical diseases, Tablet, Public, Research, News, PRV, Acquisition, TSX, Drug development, Population health, Cutaneous leishmaniasis, Canada Business Corporations Act, FDA, Transaction, Government, Growth, Entrepreneurship, Skin infection, Share, Procurement, WHO, Pharmaceutical industry

The U.S. FDA's approval of LIKMEZ highlighted Appili’s capacity to identify and develop significant opportunities within the infectious disease domain.

Key Points: 
  • The U.S. FDA's approval of LIKMEZ highlighted Appili’s capacity to identify and develop significant opportunities within the infectious disease domain.
  • Appili licensed the manufacturing and commercialization rights in the U.S. and other selected territories to Saptalis Pharmaceuticals, LLC (“Saptalis”).
  • Appili, in collaboration with Saptalis, continued the product's development, ultimately achieving FDA approval in the United States.
  • With FDA approval, future revenue is expected to be derived from milestone payments and royalties from Saptalis under the license agreement.

Venture Capital Cross announces VC Portal Launch @ VCCross.com

Retrieved on: 
Monday, March 25, 2024
Crypto, Andrew Ross Sorkin, Market, Astra, Home warranty, Skin infection, Education, Research, Fungus, Bacteria, AI, POC, Innovation system, Ice, FINRA, Artificial intelligence

KNOXVILLE, Tenn., March 25, 2024 /PRNewswire/ -- Venture Capital Cross @ vccross.com announces the launch of its cloud based private markets portal, where investors can access venture capital and private equity deals at any stage.

Key Points: 
  • KNOXVILLE, Tenn., March 25, 2024 /PRNewswire/ -- Venture Capital Cross @ vccross.com announces the launch of its cloud based private markets portal, where investors can access venture capital and private equity deals at any stage.
  • Venture Capital Cross is a division of COVA Capital Partners, LLC a registered broker-dealer and FINRA member, which has been developing a cloud based system to manage deal flow in any private market stage.
  • We believe that high growth is tied to high quality, and this complements our successful secondary market business," says Joseph Gelet Sr, Director of Private Markets for Venture Capital Cross.
  • Venture Capital Cross recently completed a Reg CF campaign for Free Speech platform Gab.com as well as secondary market transactions in Celonis, Dataminr, Addepar, Cerebras, Jasper AI, Weights & Biases, Neuralink, Anduril, and others.

AMERICAN ACADEMY OF DERMATOLOGY: HOW TO CHECK FOR BEDBUGS

Retrieved on: 
Thursday, March 14, 2024
Biting, Skin infection, Chickenpox, Human, Anxiety, Seed, Thought, Rash, Skin, Allergy, FAAD, AAD, Blood, Bed bug, Frustration, Blister, Nail, Spider, Bed, Baggage

ROSEMONT, Ill., March 14, 2024 /PRNewswire/ -- Bedbugs can make you itch just by thinking about them. These tiny, reddish-brown insects that feed on blood are notorious for infiltrating hotel rooms and luggage, hitchhiking their way back to a new home virtually undetected.

Key Points: 
  • Although bedbug bites are not usually dangerous, bedbugs can come home with you, infest your home, and cause a great deal of discomfort and anxiety.
  • If bedbugs are present in your home, you will likely find bites on your body.
  • There are fewer spots for bedbugs to hide in bathrooms, so you can check your room without worry.
  • These tips are demonstrated in " How to check for bedbugs ," a video posted to the AAD website and YouTube channel .

Global Cephalosporin Drug Market Forecast to Reach USD 21.9 Billion by 2029: Exceptional Growth in Bacterial Infection Treatments Fuels Market Expansion - ResearchAndMarkets.com

Retrieved on: 
Friday, February 23, 2024
General Health, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Generation, Urinary tract infection, Skin infection, Growth, SWOT, Skin, Respiratory tract infection, Administration, Prevalence, Knowledge, Infection, Pharmaceutical industry

A sterling analysis of the global cephalosporin drug market has been conducted, encapsulating the various segments such as generation, route of administration, and application.

Key Points: 
  • A sterling analysis of the global cephalosporin drug market has been conducted, encapsulating the various segments such as generation, route of administration, and application.
  • This report delves into the current industry patterns, the comprehensive competitive landscape, and the elaborative market dynamics from 2019 to 2029.
  • Highlighting the significance of bacterial infections as a driving force behind the growth of the cephalosporin drug market, the report underscores the increasing global demand for effective antibiotics.
  • With a robust forecast predicting substantial growth, this report is an essential asset for those seeking to navigate the complex pathways of the cephalosporin drug market.

Hugel Receives FDA Approval in the United States of Letybo (letibotulinumtoxinA-wlbg) for Injection for the Treatment of Glabellar Lines

Retrieved on: 
Monday, March 4, 2024
Food and Drug Administration, Headache, MD, AB toxin, Catherine Disher, FDA, Blinking, Food, Vitamin, Dizziness, Hugel & Fils, Risk, Allergy, Human, Telecanthus, Rash, Patient, Skin infection, Child, Bleeding, Medication, Wheeze, Face, Pharmaceutical industry

NEWPORT BEACH, Calif., March 4, 2024 /PRNewswire/ -- Hugel America, Inc., a division of Hugel Inc., a global leader in the medical aesthetics industry, today announced it received United States (U.S.) Food and Drug Administration (FDA) approval on its neurotoxin, Letybo to treat moderate-to-severe glabellar (frown) lines in adults. In the coming months, Hugel plans to accelerate its transition for approved medical use with the goal of launching to aesthetic clinicians in the back half of 2024.

Key Points: 
  • NEWPORT BEACH, Calif., March 4, 2024 /PRNewswire/ -- Hugel America, Inc., a division of Hugel Inc., a global leader in the medical aesthetics industry, today announced it received United States (U.S.) Food and Drug Administration (FDA) approval on its neurotoxin, Letybo to treat moderate-to-severe glabellar (frown) lines in adults.
  • This is a huge achievement for Hugel as we focus on becoming a top aesthetics brand in the U.S.," stated James Hartman, President, Hugel America.
  • Joely Kaufman, MD, commented, "The results from the clinical trials for letibotulinumtoxinA demonstrate efficacy, and a convincing safety profile in the treatment of glabellar lines1.
  • FDA approval is supported by positive results from three completed phase III trials that enrolled more than 1,000 subjects in the U.S. and Europe1.

BOTOX® Cosmetic (onabotulinumtoxinA) Announces Its 2024 Grant Program Supporting Women Entrepreneurs

Retrieved on: 
Wednesday, February 21, 2024
Allergy, ABBV, Senior, Woman, Injection, Research, ALS, Paratriathlon, Headache, Neck pain, Workplace, Education, Catherine Disher, Dream, Vitamin, Small business, Dizziness, Mentorship, Asthma, AbbVie, Weakness, Risk, AB toxin, Pain, Face, Human, COMMUNITY, BIPOC, Postal, Eyebrow, Confidence, Rash, Skin infection, Breast milk, Burnout, Myasthenia gravis, Eyelid, Lambert–Eaton myasthenic syndrome, Medication, Wheeze, Fatigue, Xerostomia, Partnership, Pharmaceutical industry

IRVINE, Calif., Feb. 21, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that applications are open for the 2024 BOTOX® Cosmetic grant program supporting women entrepreneurs. BOTOX® Cosmetic partnered with IFundWomen to launch the program in 2023, and in the second year, will award a new group of 20 women entrepreneurs each with $25,000 grants to fund and grow their businesses. Additionally, BOTOX® Cosmetic continues to support these businesses through mentorship, coaching, crowdfunding, and community.

Key Points: 
  • FOR THE SECOND YEAR, BOTOX® COSMETIC WILL HELP WOMEN ENTREPRENEURS CLOSE THE CONFIDENCE GAP THROUGH FUNDING, MENTORSHIP, COACHING, AND COMMUNITY
    IRVINE, Calif., Feb. 21, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that applications are open for the 2024 BOTOX® Cosmetic grant program supporting women entrepreneurs.
  • We are grateful to learn from them and thrilled to continue this program into a second year with a new cohort of extraordinary women entrepreneurs."
  • I am forever grateful to this program for connecting me to a group of women entrepreneurs who together are helping to bridge the Confidence Gap.
  • Starting today, women entrepreneurs across the country can apply for the BOTOX® Cosmetic x IFundWomen grant at www.botoxcosmetic.com/realimpact for the chance to be one of 20 recipients.

U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum

Retrieved on: 
Friday, January 5, 2024
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Food, FAAD, Molluscum contagiosum, Caregiver, Parent, American Academy, Skin infection, Nitric oxide, Patient, Viral, Clinical

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the U.S. Food and Drug Administration (FDA) has approved ZELSUVMI™ (berdazimer topical gel, 10.3%) for the treatment of molluscum contagiosum (molluscum) in adults and pediatric patients one year of age and older.i The FDA approved ZELSUVMI as the first novel drug for the treatment of molluscum infections.

Key Points: 
  • Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the U.S. Food and Drug Administration (FDA) has approved ZELSUVMI™ (berdazimer topical gel, 10.3%) for the treatment of molluscum contagiosum (molluscum) in adults and pediatric patients one year of age and older.i The FDA approved ZELSUVMI as the first novel drug for the treatment of molluscum infections.
  • vi
    “It is nice to see that molluscum contagiosum is finally getting the attention it deserves.
  • Nitric oxide has been shown to have antiviral properties.vii The mechanism of action of ZELSUVMI for the treatment of molluscum contagiosum is unknown.
  • With ZELSUVMI, patients now have an at-home treatment option available.”
    ZELSUVMI is expected to be available in the United States in the second half of 2024.

Scabies: UK facing unusually large outbreaks – and treatment shortages appear mostly to blame

Retrieved on: 
Friday, January 5, 2024
Scabies, World, Risk, Infection, Parasitism, University, School, Research, Prison, Skin, Nursing, Disease, Incidence, MITES, Human, Ivermectin, Heart, Malathion, Permethrin, News, Chronic kidney disease, Skin infection, Groin, Disease outbreak, COVID-19, Security agency, Impetigo, World Health Organization, Patient, Diagnosis, Time, Safety, Mite, Finger, Rash

Outbreaks happen regularly – with an estimated 450 million cases occurring globally each year.

Key Points: 
  • Outbreaks happen regularly – with an estimated 450 million cases occurring globally each year.
  • But since the start of winter, outbreaks in the UK have been higher than normal.
  • While there a probably a few factors that can explain this spike, treatment shortages appear to be at the heart of it.
  • The skin rash is also more severe, with a crust over the surface of the infected area.
  • Itching may take up to a month to completely subside after treatment.

Outbreak causes

  • This means mites spread more easily in places where people come into close contact with each other for extended periods of time – such as schools, universities and prisons.
  • Residential care and nursing homes are particularly high-risk settings for scabies outbreaks, with vulnerable populations and staff members alike at risk of infection.
  • Another factor in the outbreak could be stigma against having scabies, with many people claiming the disease is caused by being unclean or a lack of bathing.
  • In reality, there’s no good evidence about a lack of washing being a risk factor.
  • While some evidence suggests that scabies incidence is higher in the winter, in reality outbreaks can happen at any time of the year.
  • Since September 2023, there’s been a shortage of both permethrin and malathion in the UK due to supply issues.

Preventing infection

  • If anyone has symptoms that might be scabies or another skin infection, such as itching and a rash or skin wounds, these should be reported to a doctor or healthcare provider as early as possible.
  • This is especially important if they have potentially been in close contact with a known case.
  • Scabies outbreaks can be brought under control – but diagnosis and treatment as early as possible is required for that to happen.


Michael Head has previously received funding from the Bill & Melinda Gates Foundation and the UK Department for International Development, and currently receives funding from Research England and the UK Medical Research Foundation.

ADC Therapeutics Provides Business Updates

Retrieved on: 
Thursday, January 4, 2024
ALT, MTD, MD Anderson Cancer Center, Lung cancer, Aes, DLBCL, DLT, PSMA, Sarcoma, Progression-free survival, Fatigue, KAAG1, Neutropenia, Hyperglycemia, Society, Therapy, Follicular lymphoma, Clinical trial, AXL, ASH, University, Rituximab, Skin infection, Pancreatic cancer, Periodic breathing, Patient, PFS, ADC, CD22, NSCLC, Security (finance), Pharmaceutical industry

LAUSANNE, Switzerland, Jan. 04, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today provided business updates.

Key Points: 
  • ZYNLONTA®1 4Q 2023 net sales expected to be ~$16.5 million, a double-digit percentage increase as compared to 3Q 2023
    ADCT-601 (targeting AXL): Reached MTD and currently in dose optimization; Early signs of antitumor activity in both monotherapy and in combination
    LAUSANNE, Switzerland, Jan. 04, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today provided business updates.
  • “During 2023, we took a number of decisive actions to help position the Company for success in 2024 and beyond.
  • We prioritized our pipeline, strengthened our organization and implemented a disciplined capital allocation model to generate cost efficiencies,” said Ameet Mallik, Chief Executive Officer of ADC Therapeutics.
  • The Company ended the fourth quarter of 2023 with cash and cash equivalents of ~$278.5 million.